Chronic Periodontitis Pipeline Insight, Clinical Trials, and Emerging Therapies Report 2023 | Key Companies- Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, Perioc, and Others

DelveInsight's, "Chronic Periodontitis Pipeline Insights 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Chronic Periodontitis pipeline landscape. It covers the Chronic Periodontitis pipeline drug profiles, including Chronic Periodontitis clinical trials and nonclinical stage products. It also covers the Chronic Periodontitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Periodontitis Pipeline Report

• DelveInsight's Chronic Periodontitis Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Chronic Periodontitis treatment.

• The leading Chronic Periodontitis Companies include Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, Perioc, CD Pharma India Pvt. Ltd., Next Gen Pharma India Pvt. Ltd, Johnson & Johnson, Dexcel Pharma Technologies Ltd., Colgate Palmolive, Sunstar Americas, Ondine Research Laboratories, and others

• Promising Chronic Periodontitis Pipeline Therapies include minocycline HCl 2.1%, Administration of Metronidazole plus Amoxicillin, PerioChip, Probiotic (Inersan), Lactobacillus brevis CD2 Lozenges, Doxycycline, Inersan, and others

• The Chronic Periodontitis companies and academics are working to assess challenges and seek opportunities that could influence in Chronic Periodontitis R&D. The Chronic Periodontitis therapies under development are focused on novel approaches to treat/improve in Chronic Periodontitis.

Request a sample and discover the recent breakthroughs happening in the Chronic Periodontitis Pipeline landscape @ Chronic Periodontitis Pipeline Outlook- https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Periodontitis Overview
Periodontal disease and dental caries are the most common diseases in the oral cavity. Chronic periodontitis is one of the periodontal diseases. It is a long-lasting inflammatory disease affecting the soft and hard tissues around the teeth and it is common worldwide. This disease is related to common and preventable biological risk factors (e.g., high blood pressure, high blood cholesterol, diabetes, genetic factors, and obesity) and behavioral risk factors (e.g., an unhealthy diet, physical inactivity, and tobacco use). Chronic periodontitis is ideally diagnosed at the beginning of the disease.

Chronic Periodontitis Emerging Drugs Profile

• ST 266: Noveome
ST266 is a cell-free biologic made by culturing a novel population of human amnion-derived cells. Through a proprietary culturing method, these cells produce an array of growth factors and cytokines, known as the secretome, which promote cellular survival and reduce inflammation.

For further information, refer to the detailed Chronic Periodontitis Drugs Launch, Chronic Periodontitis Developmental Activities, and Chronic Periodontitis News, click here for Chronic Periodontitis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Periodontitis Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Chronic Periodontitis. The companies which have their Chronic Periodontitis drug candidates in the most advanced stage, i.e. Phase II include, Noveome

Chronic Periodontitis Pipeline Segmentation

Phases
DelveInsight's report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Chronic Periodontitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous

Molecule Type
Products have been categorized under various Molecule types such as
• Peptide
• Protein
• Propylene glycols
• Cell Therapy
 

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination

Find out more about the Chronic Periodontitis Pipeline Segmentation, Therapeutics Assessment, and Chronic Periodontitis Emerging Drugs @ Chronic Periodontitis Treatment Landscape- https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Periodontitis Pipeline Report

• Coverage- Global

• Chronic Periodontitis Companies- Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, Perioc, CD Pharma India Pvt. Ltd., Next Gen Pharma India Pvt. Ltd, Johnson & Johnson, Dexcel Pharma Technologies Ltd., Colgate Palmolive, Sunstar Americas, Ondine Research Laboratories, and others

• Chronic Periodontitis Pipeline Therapies- minocycline HCl 2.1%, Administration of Metronidazole plus Amoxicillin, PerioChip, Probiotic (Inersan), Lactobacillus brevis CD2 Lozenges, Doxycycline, Inersan, and others

• Chronic Periodontitis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Chronic Periodontitis Pipeline Companies and Therapies, click here @ Chronic Periodontitis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chronic Periodontitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Periodontitis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase II)
8. Ciclosporin topical gel: Perioc
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. VAX PG: Vaxcyte
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Chronic Periodontitis Key Companies
24. Chronic Periodontitis Key Products
25. Chronic Periodontitis- Unmet Needs
26. Chronic Periodontitis- Market Drivers and Barriers
27. Chronic Periodontitis- Future Perspectives and Conclusion
28. Chronic Periodontitis Analyst Views
29. Chronic Periodontitis Key Companies
30. Appendix

Got Queries? Find out the related information on Chronic Periodontitis Mergers and acquisitions, Chronic Periodontitis Licensing Activities @ Chronic Periodontitis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.